home / stock / mdma:cc / mdma:cc news

MDMA:CC News and Press, Pharmala Biotech Holdings Inc. From 07/25/25

Stock Information
Company Name: Pharmala Biotech Holdings Inc.
Stock Symbol: MDMA:CC
Market: CNQC
Website: pharmala.ca
Menu
MDMA:CC MDMA:CC Quote MDMA:CC Short MDMA:CC News MDMA:CC Articles MDMA:CC Message Board
Get MDMA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
MDMA:CC - PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of ...
MDMA:CC - PharmAla Files Preliminary Base Shelf Prospectus

TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaN...

MDMA:CC - PharmAla Completes Shipment of LaNeo(TM) MDMA to Yale University, Provides Investor Update

TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaN...

MDMA:CC - PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of M...
MDMA:CC - PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MD...

MDMA:CC - US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

2025-05-08 16:15:00 ET When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry . However, the sector is seeing a res...

MDMA:CC - PharmAla Issues Q2 Financial Statements

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of...
MDMA:CC - PharmAla Contracts with Partner to Act as US Distributor

TORONTO, March 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its La...

MDMA:CC - PharmAla Completes Shipment of LaNeo(TM) MDMA to the University of Washington    

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its La...

MDMA:CC - PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its La...
Previous 10 Next 10